¹⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay

E-ISSN： 1874-4729|9|1|85-93

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.9, Iss.1, 2015-11, pp. : 85-93

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of ¹⁷⁷Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 64-70

Bentham Science Publishers

Access to resources Recommend Favorite

Chemistry and bifunctional chelating agents for binding ¹⁷⁷Lu

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 86-94

Bentham Science Publishers

Access to resources Recommend Favorite

Standardization of Procedures for the Preparation of ¹⁷⁷Lu- and ⁹⁰Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation

Current Radiopharmaceuticals, Vol. 8, Iss. 1, 2015-05 ,pp. : 62-68

Bentham Science Publishers

Access to resources Recommend Favorite

Radiation Dosimetry Aspects of ¹⁷⁷Lu

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 139-144

Bentham Science Publishers

Access to resources Recommend Favorite

Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷Lu and Conjugated to Peptides

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 150-159

Bentham Science Publishers

Access to resources Recommend Favorite